Copyright Reports & Markets. All rights reserved.

Global Recombinant Vaccines Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Recombinant Vaccines

      • 1.1 Definition of Recombinant Vaccines
      • 1.2 Recombinant Vaccines Segment by Type
        • 1.2.1 Global Recombinant Vaccines Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Subunit Recombinant Vaccines
        • 1.2.3 Attenuated Recombinant Vaccines
        • 1.2.4 Vector Recombinant Vaccines
      • 1.3 Recombinant Vaccines Segment by Applications
        • 1.3.1 Global Recombinant Vaccines Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Recombinant Human Vaccines
        • 1.3.3 Animal Recombinant Vaccines
      • 1.4 Global Recombinant Vaccines Overall Market
        • 1.4.1 Global Recombinant Vaccines Revenue (2014-2025)
        • 1.4.2 Global Recombinant Vaccines Production (2014-2025)
        • 1.4.3 North America Recombinant Vaccines Status and Prospect (2014-2025)
        • 1.4.4 Europe Recombinant Vaccines Status and Prospect (2014-2025)
        • 1.4.5 China Recombinant Vaccines Status and Prospect (2014-2025)
        • 1.4.6 Japan Recombinant Vaccines Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Recombinant Vaccines Status and Prospect (2014-2025)
        • 1.4.8 India Recombinant Vaccines Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Recombinant Vaccines
      • 2.3 Manufacturing Process Analysis of Recombinant Vaccines
      • 2.4 Industry Chain Structure of Recombinant Vaccines

      3 Development and Manufacturing Plants Analysis of Recombinant Vaccines

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Recombinant Vaccines Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Recombinant Vaccines
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Recombinant Vaccines Production and Capacity Analysis
      • 4.2 Recombinant Vaccines Revenue Analysis
      • 4.3 Recombinant Vaccines Price Analysis
      • 4.4 Market Concentration Degree

      5 Recombinant Vaccines Regional Market Analysis

      • 5.1 Recombinant Vaccines Production by Regions
        • 5.1.1 Global Recombinant Vaccines Production by Regions
        • 5.1.2 Global Recombinant Vaccines Revenue by Regions
      • 5.2 Recombinant Vaccines Consumption by Regions
      • 5.3 North America Recombinant Vaccines Market Analysis
        • 5.3.1 North America Recombinant Vaccines Production
        • 5.3.2 North America Recombinant Vaccines Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Recombinant Vaccines Import and Export
      • 5.4 Europe Recombinant Vaccines Market Analysis
        • 5.4.1 Europe Recombinant Vaccines Production
        • 5.4.2 Europe Recombinant Vaccines Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Recombinant Vaccines Import and Export
      • 5.5 China Recombinant Vaccines Market Analysis
        • 5.5.1 China Recombinant Vaccines Production
        • 5.5.2 China Recombinant Vaccines Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Recombinant Vaccines Import and Export
      • 5.6 Japan Recombinant Vaccines Market Analysis
        • 5.6.1 Japan Recombinant Vaccines Production
        • 5.6.2 Japan Recombinant Vaccines Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Recombinant Vaccines Import and Export
      • 5.7 Southeast Asia Recombinant Vaccines Market Analysis
        • 5.7.1 Southeast Asia Recombinant Vaccines Production
        • 5.7.2 Southeast Asia Recombinant Vaccines Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Recombinant Vaccines Import and Export
      • 5.8 India Recombinant Vaccines Market Analysis
        • 5.8.1 India Recombinant Vaccines Production
        • 5.8.2 India Recombinant Vaccines Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Recombinant Vaccines Import and Export

      6 Recombinant Vaccines Segment Market Analysis (by Type)

      • 6.1 Global Recombinant Vaccines Production by Type
      • 6.2 Global Recombinant Vaccines Revenue by Type
      • 6.3 Recombinant Vaccines Price by Type

      7 Recombinant Vaccines Segment Market Analysis (by Application)

      • 7.1 Global Recombinant Vaccines Consumption by Application
      • 7.2 Global Recombinant Vaccines Consumption Market Share by Application (2014-2019)

      8 Recombinant Vaccines Major Manufacturers Analysis

      • 8.1 Merck & Co., Inc
        • 8.1.1 Merck & Co., Inc Recombinant Vaccines Production Sites and Area Served
        • 8.1.2 Merck & Co., Inc Product Introduction, Application and Specification
        • 8.1.3 Merck & Co., Inc Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Green Cross Corporation
        • 8.2.1 Green Cross Corporation Recombinant Vaccines Production Sites and Area Served
        • 8.2.2 Green Cross Corporation Product Introduction, Application and Specification
        • 8.2.3 Green Cross Corporation Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Pfizer Inc.
        • 8.3.1 Pfizer Inc. Recombinant Vaccines Production Sites and Area Served
        • 8.3.2 Pfizer Inc. Product Introduction, Application and Specification
        • 8.3.3 Pfizer Inc. Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Bayer AG
        • 8.4.1 Bayer AG Recombinant Vaccines Production Sites and Area Served
        • 8.4.2 Bayer AG Product Introduction, Application and Specification
        • 8.4.3 Bayer AG Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Sanofi S A.
        • 8.5.1 Sanofi S A. Recombinant Vaccines Production Sites and Area Served
        • 8.5.2 Sanofi S A. Product Introduction, Application and Specification
        • 8.5.3 Sanofi S A. Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Protein Science Corporation
        • 8.6.1 Protein Science Corporation Recombinant Vaccines Production Sites and Area Served
        • 8.6.2 Protein Science Corporation Product Introduction, Application and Specification
        • 8.6.3 Protein Science Corporation Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 GlaxoSmithKline Plc.
        • 8.7.1 GlaxoSmithKline Plc. Recombinant Vaccines Production Sites and Area Served
        • 8.7.2 GlaxoSmithKline Plc. Product Introduction, Application and Specification
        • 8.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Novartis AG
        • 8.8.1 Novartis AG Recombinant Vaccines Production Sites and Area Served
        • 8.8.2 Novartis AG Product Introduction, Application and Specification
        • 8.8.3 Novartis AG Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Bharat Biotech
        • 8.9.1 Bharat Biotech Recombinant Vaccines Production Sites and Area Served
        • 8.9.2 Bharat Biotech Product Introduction, Application and Specification
        • 8.9.3 Bharat Biotech Recombinant Vaccines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served

      9 Development Trend of Analysis of Recombinant Vaccines Market

      • 9.1 Global Recombinant Vaccines Market Trend Analysis
        • 9.1.1 Global Recombinant Vaccines Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Recombinant Vaccines Regional Market Trend
        • 9.2.1 North America Recombinant Vaccines Forecast 2019-2025
        • 9.2.2 Europe Recombinant Vaccines Forecast 2019-2025
        • 9.2.3 China Recombinant Vaccines Forecast 2019-2025
        • 9.2.4 Japan Recombinant Vaccines Forecast 2019-2025
        • 9.2.5 Southeast Asia Recombinant Vaccines Forecast 2019-2025
        • 9.2.6 India Recombinant Vaccines Forecast 2019-2025
      • 9.3 Recombinant Vaccines Market Trend (Product Type)
      • 9.4 Recombinant Vaccines Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Recombinant Vaccines Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
        These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
        Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
        There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.

        The global Recombinant Vaccines market was valued at 880 million US$ in 2018 and will reach 1400 million US$ by the end of 2025, growing at a CAGR of 6.0% during 2019-2025.
        This report focuses on Recombinant Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall Recombinant Vaccines market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Recombinant Vaccines in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Recombinant Vaccines manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Merck & Co., Inc
        Green Cross Corporation
        Pfizer Inc.
        Bayer AG
        Sanofi S A.
        Protein Science Corporation
        GlaxoSmithKline Plc.
        Novartis AG
        Bharat Biotech

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Subunit Recombinant Vaccines
        Attenuated Recombinant Vaccines
        Vector Recombinant Vaccines

        Segment by Application
        Recombinant Human Vaccines
        Animal Recombinant Vaccines

        Buy now